Published in AIDS Vaccine Week, May 15th, 2006
Study 1: Levels of C-reactive protein assess the efficacy of pneumococcal conjugate vaccine in preventing pneumonia.
"This study explored whether C-reactive protein (CRP) and/or procalcitonin levels were useful to measure vaccine efficacy (VE) and impact against the burden of pneumonia of a 9-valent pneumococcal conjugate vaccine (PCV), compared with chest radiograph-confirmed alveolar consolidation (CXR-AC) as an outcome.
"Sera obtained from children participating in a phase 3 PCV efficacy trial who were hospitalized for treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Vaccine Week
Source: AIDS Vaccine Week (2006-05-15)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.